Exact Sciences News

Should You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)?

Yahoo FinanceAug 23 08:26 ET

Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?

Yahoo FinanceAug 22 09:55 ET

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Zacks Aug 22 08:35 ET

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Zacks Aug 22 08:00 ET

Here's Why Baron Opportunity Fund Sold Its Stake in Exact Sciences Corp (EXAS)

Yahoo FinanceAug 21 08:08 ET

Exact Sciences Kicks off Multi-cancer Detection Study

Yahoo FinanceAug 21 07:13 ET

Exact Sciences Launches Multi-Cancer Early Detection Study With 25K Patients, Supported by FDA Authorization

BenzingaAug 20 07:07 ET

Express News | Exact Sciences Announces First Patient Enrolled in Its Multi-Cancer Early Detection (Mced) Falcon Registry Real-World Evidence Study

ReutersAug 20 07:00 ET

Express News | Exact Sciences Shares Are Trading Higher After the Company Shared New Modeling Data on the Projected Impact of Its Cologuard Test Since Its FDA Approval

BenzingaAug 15 15:11 ET

Glenview Capital's Q2 Moves Include Selling Broadcom After Just One Quarter, Exiting Meta

Seeking AlphaAug 15 14:22 ET

Express News | Exact Sciences Shared New Modeling Data Describing The Projected Impact Of The Cologuard Test On Patients, Health Care Professionals, And The U.S. Health Care System Since Its FDA Approval 10 Years Ago

BenzingaAug 15 07:10 ET

New Modeling Data Show the Cologuard Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

BusinesswireAug 15 07:00 ET

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

Zacks Aug 14 09:30 ET

9 Health Care Stocks Whale Activity In Today's Session

BenzingaAug 13 13:35 ET

Exact Sciences Corporation (NASDAQ:EXAS) Shares Fly 30% But Investors Aren't Buying For Growth

Simply Wall StAug 9 06:22 ET

Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.

With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.

Zhitong FinanceAug 8 02:55 ET

Express News | Exact Sciences Corp : Piper Sandler Cuts Target Price to $75 From $80

ReutersAug 5 10:00 ET

Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)

TipRanksAug 5 02:21 ET · Ratings

DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?

BenzingaAug 4 10:32 ET

Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70

Moomoo NewsAug 3 01:32 ET · Ratings